2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase

Journal of Medicinal Chemistry

Volumn 41, Issue 6, 1998, Pages 913-918

  Rosowsky, Andre ^a   Papoulis, Andrew T ^a   Queener, Sherry F ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 [2 (3,4,5 TRIMETHOXYPHENYL)ETHYL] 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDINE; 2,4 DIAMINO 5 [3 (3,4,5 TRIMETHOXYPHENYL)PROPYL] 5H 6,7 DIHYDROCYCLOPENTA[D]PYRIMIDINE; DIHYDROFOLATE REDUCTASE INHIBITOR; TRIMETHOPRIM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; DRUG SYNTHESIS; ENZYME INHIBITION; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII;

ANIMALS; FOLIC ACID ANTAGONISTS; LIVER; PNEUMOCYSTIS; PYRIMIDINES; RATS; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; TRIMETHOPRIM;

EID: 0032510379     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970614n     Document Type: Article

References (36)

1. Masur, H. Problems in the management of opportunistic infections in patients infected with human immunodeficiency virus. J. Infect. Dis. 1990, 161, 858-864.
2. Kontoyannis, D. P.; Rubin, R. H. Infection in the organ transplant recipient. An overview. Infect. Dis. Clin. North Am. 1995, 9, 811-822.
3. Sparano, J. A.; Sara, C. Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. Current Opin. Oncol. 1996, 8, 392-399.
4. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
5. Leoung, G. S.; Mills, J.; Hopewell, P. C.; Hughes, W.; Wofsy, C. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired imunodeficiency syndrome. Ann. Intern. Med. 1986, 705, 45-48.
6. Fischl, M. A.; Dickinson, G. M.; La Voie, L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. J. Am. Med. Assoc. 1988, 105, 45-48.
7. Leport, C.; Raffi, F., Matheron, S.; Katlama, C.; Regnier, B.; Saimot, A. F.; March, C.; Vedrenne, C.; Vilde, J. L. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am. J. Med. 1988, 84, 94-100.
8. de Gans, J.; Portegies, P.; Reiss, P. Troost, D.; van Gool, T.; Lange, J. M. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J. Acq. Immune Defic. Syndr. 1992, 5, 137-142.
9. Allegra, C. J.; Chabner, B. A.; Tuazon, C. U.; Ogata-Arakaki, D.; Baird, B.; Drake, J. C.; Simmons, J. T.; Lack, E. E.; Shelhamer, J. H.; Balis, F.; Walker, R.; Kovacs, J. A.; Lane, H. C.; Masur, H. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 1987, 317, 978-985.
10. Masur, H.; Polis, M. A.; Tuazon, C. U.; Ogata-Arakaki, D.; Kovacs, J. A.; Katz, D.; Hilt, D.; Simmons, T.; Feuerstein, I.; Lindgren, B.; Lane, H. C.; Chabner, B. A.; Allegra, C. J. Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis. J. Infect. Dis. 1989, 160, 312-320.
11. Falloon, J.; Allegra, C. J.; Kovacs, J.; O'Neill, D.; Ogata-Arakaki, D.; Feuerstein, I.; Polis, M.; Davey, R.; Lane, H. C.; LaFon, S.; Rogers, M.; Zunich, K.; Zurlo, J.; Tuazon, C.; Parenti, D.; Simon, G.; Masur, H. Piritrexim with leucovorin for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Clin. Res. 1990; 38, 361A.
12. Kotake, Y.; Iijima, A.; Yoshimatsu, K.; Tamai, N.; Ozawa, Y.; Koyanagi, N.; Kitoh, K.; Nomura, H. Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[ω-(2-amino-4-substituted-6,7-dihydrocyclopentarrf]pyrimidin-5-yl) alkyl]benzoyl]-L-glutamic acids. J. Med. Chem. 1994, 37, 1616-1624.
13. Kotake, Y.; Okauchi, T.; Iijima, A.; Yoshimatsu, K.; Nomura, H. Novel 6-5 fused ring heterocycle benzoyl isosters of 2,4-diammo-6,7-dihyadro-5H-cyclopenta[d]jpyrimidine antifolate. Chem. Pharm. Bull. 1995, 43, 829-841.
14. McGuire, J. J.; Bergoltz, V. V.; Heitzman, K. J.; Haile, W. H.; Russell, C. A.; Bolanowska, E. E.; Kotake, Y.; Haneda, T.; Nomura, H. Novel 6,5-fused ring heterocyclic antifolates: Bio-chemical and biological characterization. Cancer Res. 1994, 54, 2673-2679.
15. Miwa, T-Hitaka, T.; Akimoto, H.; Nomura, H. Novel pyrrolo [2,3-d]pyrimidine antifolates: synthesis and antitumor activities. J. Med. Chem. 1991, 34, 555-560.
16. Miwa, T.; Hitaka, T.; Akimoto, H. A novel synthetic approach to pyrrolo[2,3-d]pyrimidine antifolates. J. Org. Chem. 1993, 58, 1696-1701.
17. Shih, C.; Gossett, L. S. The synthesis of N-{2-amino-4-substituted [(pyrrolo[2, 3-d]pyrimidine-5-yl)ethyl]benzoyl}-L-glutamic acids as antineoplastic agents. Heterocycles 1993, 35, 825-841.
18. Aso, K.; Hitaka, T.; Yukishige, K.; Ootsu, K.; Akimoto, H. Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom. Chem. Pharm. Bull. 1995, 43, 256-261.
19. Taylor, E. C.; Patel, H. H.; Jun, J.-G. A one-step ring transformation/ring annulation approach to pyrrolo[2,3-d]pyrimidines. A new synthesis of the potent DHFR inhibitor TNP-351. J. Org. Chem. 1995, 60, 6684-6687.
20. Taylor, E. C.; Mao, Z. A ring-transformation/ring annulation strategy for the synthesis of the DHFR inhibitor, TNP-351: A correction. J. Org. Chem. 1996, 61, 7973-7974.
21. Gangjee, A.; Devraj, R.; McGuire, J. J.; Kisliuk, R. L.; Queener, S. F.; Barrows, L. R. Classical and nonclassical furo[2, 3-d]-pyrimidines as novel antifolates: Synthesis and biological activities. J. Med. Chem. 1994, 37, 1169-1176.
22. Rosowsky, A.; Mota, C. E.; Wright, J. E.; Freisheim, J. E.; Heusner, J. J.; McCormack, J. J.; Queener, S. F. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Med. Chem. 1993, 36, 6, 3103-3112.
23. Gangjee, A.; Devraj, R.; McGuire, J. J.; Kisliuk, R. L. Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines. J. Med. Chem. 1995, 38, 3798-3805.
24. Gangjee, A.; Mavandadi, F.; Queener, S. Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases. J. Med. Chem. 1995, 38, 2158-2165.
25. Rosowsky, A.; Papoulis, A. T.; Queener, S. F. 2,4-Diaminothieno-[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase J. Med. Chem. 1997, 40, 3694-3699.
26. Rosowsky, A.; Mota, C. E.; Queener, S. F. Synthesis and antifolate activity of 2,4-diamino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine analogues of trimetrexate and piritrexim. J. Heterocycl. Chem. 1995, 32, 335-340.
27. Rapoport, H.; Campion, J. E. Synthesis of 2,3,4-trimethoxyben-zocyclohepten-6-one. J. Am. Chem. Soc. 1951, 73, 2239-2241.
28. Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
29. Chio, L.-C.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
30. Rosowsky, A.; Mota, C. E.; Wright, J. E.; Queener, S. F. 2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: Synthesis and antifolate activity. J. Med. Chem. 1994, 37, 4522-4528.
31. Rosowsky, A.; Mota, C. E.; Queener, S. F. Brominated trimetrexate analogues as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Heterocycl. Chem., 1996,33, 1959-1966.
32. Rosowsky, A.; Mota, C. E.; Queener, S. F.; Waltham, M.; Ercikan-Abali, E.; Bertino J. R. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 38, 745-752.
33. Rosowsky, A.; Forsch, R. A.; Queener, S. F. 2,4-Diaminopyrido-[3,2-d]npyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 38, 2615-2620.
34. For recent reviews of the work of several groups in this area, see: (a) Queener, S. F. New drug developments for opportunistic infections in immunocompromised patients: Pneumocystis carinii. J. Med. Chem. 1995, 35, 4739-4759. (b) Gangjee, A.; Elzein, E.; Kothare, M.; Vasudevan, A. Classical and nonclassical antifolates as potential antitumor, antipneumocystis and antitoxoplasma agents. Current Pharm. Des. 1996, 2, 263-280.
35. For recent reviews of the work of several groups in this area, see: (a) Queener, S. F. New drug developments for opportunistic infections in immunocompromised patients: Pneumocystis carinii. J. Med. Chem. 1995, 35, 4739-4759. (b) Gangjee, A.; Elzein, E.; Kothare, M.; Vasudevan, A. Classical and nonclassical antifolates as potential antitumor, antipneumocystis and antitoxoplasma agents. Current Pharm. Des. 1996, 2, 263-280.
36. Bacon, R. G. R.; Wright, J. R. Metal ions and complexes in organic reactions. Part X. Effect of methoxy-substituents on copper-catalysed nucleophilic and reductive replacement of halogen in reactions between sodium methoxide and bromo- or iodobenzene derivatives. J. Chem. Soc. (C) 1969, 1978-1981.